| Literature DB >> 27165106 |
Jin Zhang1, John J Bowling2, David Smithson2,3, Julie Clark2, Melissa R Jacob1, Shabana I Khan1, Babu L Tekwani1,4, Michele Connelly2, Vladimir Samoylenko1,5, Mohamed A Ibrahim1, Mohamed A Zaki1,6, Mei Wang1, John P Hester1, Ying Tu2, Cynthia Jeffries2, Nathaniel Twarog2, Anang A Shelat2, Larry A Walker1,4, Ilias Muhammad7, R Kiplin Guy8.
Abstract
BACKGROUND: A diverse library of pre-fractionated plant extracts, generated by an automated high-throughput system, was tested using an in vitro anti-malarial screening platform to identify known or new natural products for lead development. The platform identifies hits on the basis of in vitro growth inhibition of Plasmodium falciparum and counter-screens for cytotoxicity to human foreskin fibroblast or embryonic kidney cell lines. The physical library was supplemented by early-stage collection of analytical data for each fraction to aid rapid identification of the active components within each screening hit.Entities:
Keywords: Alkaloids; Antimalarial; Berberis thunbergii; Drug discovery; Eugenia rigida; Natural products; Plasmodium falciparum; Spectrometry; Terpenes; UPLC-ELSD-PDA-ESI–MS
Mesh:
Substances:
Year: 2016 PMID: 27165106 PMCID: PMC4863362 DOI: 10.1186/s12936-016-1313-7
Source DB: PubMed Journal: Malar J ISSN: 1475-2875 Impact factor: 2.979
Anti-malarial activity (% activity and EC50, μg/mL) of AHTS fractions from Berberis thunbergii (extract code 80679)
| Fraction or COMBI | Primary (% activity) | Secondary (EC50, μg/mL) | |||||
|---|---|---|---|---|---|---|---|
| μg/mL | MAR3D7a | MARK1b | HEK293c | BJd | MAR3D7a | MARK1b | |
| f8/c9 | 23.68 | 43.4 | 37 | 2.15 | −0.85 | ||
| f9/c8 | 35.75 | 95.2 | 80.2 | 2.52 | 6.63 | 8.15 | 7.57 |
| f10/c7 | 23.68 | 97.4 | 95 | 8.13 | 4.91 | 0.53 | 0.63 |
| f11/c6 | 14.39 | 96.9 | 96.5 | 5.29 | 0 | 2.02 | 3.6 |
| f12/c5 | 8.37 | 92.8 | 93.4 | 7.42 | 0.7 | 0.61 | 0.81 |
| f13/c5 | 5.57 | 92 | 92.4 | 3.59 | 0.45 | 0.39 | 0.45 |
| f14/c4 | 5.11 | 89.9 | 96 | 5.05 | −0.48 | 0.86 | 2.07 |
| f15/c4 | 7.43 | 84.9 | 97.6 | 6.94 | 0.56 | 1.11 | 10.61 |
| f16/c3 | 11.14 | 84.4 | 93.7 | 10.1 | 1.13 | 0.21 | 4.77 |
| f17/c2 | 6.96 | 95.7 | 94.6 | 1.09 | 1.48 | 1.66 | 1.7 |
| f18/c2 | 5.11 | 76.9 | 39 | 3.12 | −0.94 | ||
| f19/c1 | 4.18 | 35.6 | 21.2 | 1.29 | 0.64 | ||
aChloroquine-sensitive P. falciparum strain
bChloroquine-sensitive P. falciparum strain
cHuman embryonic kidney cells
dHuman foreskin fibroblast
Fig. 1A phylogenetic tree of all screened genera. This tree was derived from both formal taxonomic classifications (e.g., family, order, class) and informal clades (e.g., rosids, asterids). Bars on the circumference indicate the total number of hits in each genus against the 3D7 and K1 P. falciparum cell lines. Hits were obtained from over 20 different species of the 46 in the entire library that were categorized as endangered or threatened. Genera in which some or all hits were derived from endangered species are marked in red. Larger groups, including many of the orders containing ≥7 genera and sub-order nodes that contained highly productive genera, are labelled
Fig. 2ELSD chromatograms of Berberis thunbergii fractions 80679-c1–80679-c9. UPLC conditions (details in Additional file 1): Fraction 80679-c1 injected by using “3 min_nonpolar_NP” method. Fractions 80679-c2–80679-c4 injected by using “3 min_NP” method. Fraction 80679-c5 injected by using “NP” method. Fractions 80679-c6–80679-c9 injected by using “3 min_polar_NP” method. Anti-plasmodium activity of the COMBI is expressed as a green or red arrow on the basis of its potency compared to its preceding fraction(s) in COMBIs, starting from the most hydrophilic fraction at the bottom (f8) and continuing to the most lipophilic (f19) fraction at the top of the figure
Fig. 3UPLC-MS-ELSD-PDA analysis of fraction 80679-c3 of Berberis thunbergii. a ELSD chromatogram; b PDA chromatogram; c positive ESI–MS TIC chromatogram; d negative ESI–MS TIC chromatogram; e–g positive ESI–MS spectra of the compounds with respective retention times of 0.85, 0.94, and 0.98 min in the PDA chromatogram; h, i negative ESI–MS spectra of the compounds with respective retention times of 0.85 and 0.94 in the PDA chromatogram; j–l UV spectra of the compounds with respective retention times of 0.85, 0.94, and 0.98 min in the PDA chromatogram. UPLC conditions: acquity UPLC BEH C18 column (2.1 × 50 mm, 1.7 μm); gradient elution with 0– 100 % ACN in 0.1 % HCOOH in 3 min
Fig. 4UPLC-MS-ELSD-PDA analysis of fraction 80679-c5 of Berberis thunbergii. a ELSD chromatogram; b PDA chromatogram; c, d positive ESI–MS BPI and negative ESI–MS TIC chromatograms, respectively; e–g positive ESI–MS spectra of the compounds with respective retention times of 2.06, 2.18, and 2.23 min in the PDA chromatogram; h, i UV spectra of the compounds with respective retention times of 2.18 and 2.23 min in the PDA chromatogram. UPLC conditions: acquity UPLC BEH C18 column (2.1 × 50 mm, 1.7 μm); gradient elution with 0–100 % ACN in 0.1 % HCOOH in 3 min
Fig. 5UPLC-MS-ELSD-PDA analysis of fraction 80679-c9 of Berberis thunbergii. a ELSD chromatogram; b PDA chromatogram; c, d positive and negative ESI–MS TIC chromatograms, respectively; e positive ESI–MS spectra of the compound with a retention time of 2.06 min in the PDA chromatogram; f UV spectra of the compound with a retention time of 2.06 min in PDA chromatogram. UPLC conditions: Acquity UPLC BEH C18 column (2.1 × 50 mm, 1.7 μm); gradient elution with 0–100 % ACN in 0.1 % HCOOH in 3 min
Fig. 6ELSD chromatogram of Eugenia rigida fractions 79575-c4–79575-c8. UPLC conditions: fractions all run by using the “3 min_NP” method (details in Additional file 1). Anti-plasmodium activity of the COMBI is expressed as a green or red arrow on the basis of its potency compared to its preceding fraction(s) in COMBIs, starting from the most hydrophilic fraction at the bottom (f14) and continuing to the most lipophilic (f18) fraction at the top of the figure
Fig. 7UPLC-MS-ELSD-PDA analysis of fraction 79575-c5 of Eugenia rigida. a ELSD chromatogram; b PDA chromatogram; c and d positive and negative ESI–MS BPI chromatograms, respectively; e, f positive ESI–MS spectra of the compounds with respective retention times of 1.87 and 1.95 min in the PDA chromatogram; g, h negative ESI–MS spectra of the compounds with respective retention times of 1.87 and 1.95 min in the PDA chromatogram; i, j UV spectra of the compounds with respective retention times of 1.87 and 1.95 min in the PDA chromatogram. UPLC conditions: Acquity UPLC BEH C18 column (2.1 × 50 mm, 1.7 μm); gradient elution with 0–100 % ACN in 0.1 % HCOOH in 3 min
Fig. 8Structure of compounds isolated from Berberis thunbergii and Eugenia rigida
Anti-malarial activity of compounds 1 and 9–13 and fractions from Berberis thunbergii and Eugenia rigida against P. falciparum
| Sample | Unit |
| Sample |
| ||
|---|---|---|---|---|---|---|
| 3D7 | K1 | 3D7 | K1 | |||
| BT-EtOHa | μg/mL | NTg | NT | ER-EtOHh | >100 | >100 |
| BT-P-Ab | μg/mL | 0.25 | 0.291 | ER-MeOHi | 2 | 1.37 |
| BT-P-Bc | μg/mL | 0.23 | 0.19 | ER-Hexj | >100 | >100 |
| BT-P–Cd | μg/mL | NT | NT | ER-Hex-33-52k | 1 | 0.6 |
| BT-P-De | μg/mL | 10 | 10 | ER-Hex-53-60l | 0.7 | 0.6 |
|
| μg/mL | 100 | 0.42 | ER-EtOAcm | >100 | >100 |
|
| μM | 0.46 | 0.44 |
| 7.7 | 4.0 |
|
| μM | 0.035 | 0.15 |
| NT | NT |
|
| μM | NT | NT |
| 0.3 | 1.1 |
a BT-EtOH EtOH extract of B. thunbergii
b BT-P-A acidic CHCl3 fraction of BT
c BT-P-B basic CHCl3 fraction of BT
d BT-P-C EtOAc fraction of BT
e BT-P-D aqueous fraction of BT
fMixture of 7 and 8
g NT not tested
h ER-EtOH EtOH extract of E. rigida
i ER-MeOH MeOH extract of ER
j ER-Hex n-hexane extract of ER
k ER-Hex-33-52 RP-CPTLC fraction of ER
l ER-Hex-53-60 RP-CPTLC fraction ER
m ER-EtOAc EtOAc extract of E. rigida